Rochester, NY 9/1/2009 3:55:13 PM
Human Genome Sciences Inc., HGSI, Down by 0.04 cents Last Trading
Human Genome Sciences Inc.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Human Genome Sciences Inc. announces that it’s after hours report market trade up to 5 cents or 25 percent to $19.85. The company stocks still off a 52-week high $22.78.
The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax.
Whisperfromwallstreet.com is a FREE award winning newsletter dedicated to uncovering stocks that are about to move. Please click here to join now.
Last Trade: 19.76
Day's Range: N/A - N/A
52wk Range: 0.00 - 22.78
Change: 0.00 (0.00%)
Volume: 0
Avg Vol (3m): 12,645,700
ABOUT Human Genome Sciences
Human Genome Sciences (HGS)is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. Albuferon and LymphoStat-B are progressing toward commercialization. In December 2008, the Company reported that Albuferon met its primary endpoint in the first of two Phase III clinical trials in chronic hepatitis C. HGS also has several drugs in earlier stages of clinical development for the treatment of cancer, led by its TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.
ABOUT WhisperFromWallStreet.com
WhisperFromWallStreet.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
WhisperFromWallStreet.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://WhisperFromWallStreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
